
Open-Angle Glaucoma - Pipeline Insight, 2024
Description
Open-Angle Glaucoma - Pipeline Insight, 2024
DelveInsight’s, “Open-Angle Glaucoma - Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Open-Angle Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Open-Angle Glaucoma: Overview
Glaucoma is an eye disease that gradually steals vision. Open-Angle Glaucoma is the most common type of glaucoma. Open-Angle Glaucoma is a chronic, progressive, and irreversible multifactorial optic neuropathy that is characterized by an open angle of the anterior chamber, optic nerve head changes, progressive loss of peripheral vision, followed by central visual field loss. Glaucoma affects 70 million people worldwide and is the second leading cause of blindness. The underlying pathology of Open-Angle Glaucoma lies in the apoptosis of retinal ganglion cells. Open-Angle Glaucoma can be clinically evaluated using a variety of diagnostic tools including optic disc changes, visual field changes, and elevated intraocular pressure. The goal of treatment of Open-Angle Glaucoma is to prevent the progression of optic nerve head changes and also the prevention of deterioration of visual field.
""Open-Angle Glaucoma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Open-Angle Glaucoma pipeline landscape is provided which includes the disease overview and Open-Angle Glaucoma treatment guidelines. The assessment part of the report embraces, in depth Open-Angle Glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Open-Angle Glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Open-Angle Glaucoma R&D. The therapies under development are focused on novel approaches to treat/improve Open-Angle Glaucoma.
This segment of the Open-Angle Glaucoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Open-Angle Glaucoma Emerging Drugs
- QLS-101: Qlaris Bio
- Razuprotafib: Aerpio Pharmaceuticals
Further product details are provided in the report……..
Open-Angle Glaucoma: Therapeutic Assessment
This segment of the report provides insights about the different Open-Angle Glaucoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Open-Angle Glaucoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Open-Angle Glaucoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Open-Angle Glaucoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Open-Angle Glaucoma drugs.
Open-Angle Glaucoma Report Insights
- Open-Angle Glaucoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Open-Angle Glaucoma drugs?
- How many Open-Angle Glaucoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Open-Angle Glaucoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Open-Angle Glaucoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Open-Angle Glaucoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Qlaris Bio
- Ocular Therapeutix
- SALVAT
- Aerpio Pharmaceuticals
- Ocularis Pharma
- PolyActiva
- AbbVie
- Annexon
- Skye Bioscience
- GrayBug
- Quark Pharmaceuticals
- QLS-101
- Travoprost ophthalmic
- SVT18412
- Razuprotafib
- Phentolamine
- PA5108
- AGN 193408 sustained-release
- ANX 007
- NB 1111
- GB 401
- QPI-1017
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Open-Angle Glaucoma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Open-Angle Glaucoma – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Open-Angle Glaucoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Open-Angle Glaucoma Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Travoprost ophthalmic: Ocular Therapeutix
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- QLS-101: Qlaris Bio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- PA5108: PolyActiva
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- NB 1111: Skye Bioscience
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Open-Angle Glaucoma Key Companies
- Open-Angle Glaucoma Key Products
- Open-Angle Glaucoma- Unmet Needs
- Open-Angle Glaucoma- Market Drivers and Barriers
- Open-Angle Glaucoma- Future Perspectives and Conclusion
- Open-Angle Glaucoma Analyst Views
- Open-Angle Glaucoma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.